article
Drug Target Review Antibodies ebook 2021
This ebook has features on the development of intranasally-delivered antibodies to combat SARS-CoV-2 and how the structure of a nanobody was determined using nuclear magnetic resonance methods.
List view / Grid view
Antibody Discovery
whitepaper
Infographic: A custom monoclonal antibody for your next project
Learn what sets Bethyl custom monoclonal antibodies quality and service apart and discover the top reasons why you should choose Forits Life Sciences for your next project.
whitepaper
Brochure: Immuno-Oncology Solutions
A wide range of tools to support your immuno-oncology research and help redefine and develop tailored, life-changing immunotherapies to fight cancer.
article
ebook: Antibody Discovery – technology and techniques to boost development
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
article
Advancing neutralising antibody therapies for COVID-19
In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.
news
Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
news
SARS-CoV-2 triggers antibodies from previous coronavirus infections
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
news
Novel nanobody combinations protect cells from SARS-CoV-2 in vitro
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
news
Assay reveals potency of neutralising antibodies in COVID-19 patients
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
news
Synthetic llama antibodies used to rescue mutated proteins
Engineered deubiquitinases combines a synthetic nanobody that recognises a protein that can rescue proteins tagged for destruction.
news
More COVID-19 research on mucosal immune system required, scientists say
Researchers have said that more COVID-19 studies should focus on the mucous membranes of the nose and mouth, to reveal insights into SARS-CoV-2 immunity.
news
Antibodies from previous COVID-19 infection protect patients for six months
A study in healthcare workers has shown that antibodies from COVID-19 infection protect individuals from reinfection for at least six months.
news
Antibody effector functions are key to combatting COVID-19, finds study
Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.
news
£4 million in funding announced to collect data on COVID-19 antibodies
UKRI will provide £4 million in funding to establish a data infrastructure for scientists in the UK to study antibodies from COVID-19 patient samples.
